Prednisone Tablets Recalled for Contamination With Wrong-Strength Tablets
Strides Pharma is recalling Prednisone 20 mg tablets due to contamination with 2.5 mg tablets. No illnesses have been reported, but patients may receive incorrect doses.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving contamination with wrong-strength tablets in a prescription corticosteroid medication. No illnesses reported, but the contamination creates risk of dosing errors with a prescription medication, qualifying as a risk-of-harm product under Score 3 criteria.
Plain-English summary
Strides Pharma Inc. is recalling Prednisone Tablets USP, 20 mg, because some bottles contain a 2.5 mg tablet mixed in with the 20 mg tablets. This is an FDA Class II recall.
The contamination creates a risk that patients may inadvertently receive the wrong dose of the medication. No illnesses or injuries have been reported to date.
The recall affects approximately 1,032 bottles with lot number 7248988B and an expiration date of 9/2023, distributed nationwide throughout the United States.
Patients who have a bottle from this lot should contact their pharmacy or healthcare provider to confirm whether their supply is affected and to obtain a replacement.
The recalled product
- Product
- PREDNISONE (PREDNISONE)
- Brand
- PREDNISONE
- Manufacturer
- Strides Pharma Inc.
- Category
- Drug — Prescription Tablets
- Hazard
- foreign-tablet
- dosing-error
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 7248988B
- Exp 9/2023
UPCs (3)
- 0364380949060
- 0364380785064
- 0364380784067
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01